{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:45:38Z","timestamp":1787237138053,"version":"build-2736575974"},"reference-count":16,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.2217\/imt-2017-0177","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T05:15:00Z","timestamp":1519362900000},"page":"341-344","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Malignant Mesothelioma Clinical Trial Combines Immunotherapy Drugs"],"prefix":"10.1080","volume":"10","author":[{"given":"Monica S","family":"Chatwal","sequence":"first","affiliation":[{"name":"Division of Medicine, Division of Hematology\/Oncology, University of South Florida\/H Lee Moffitt Cancer Center, Tampa, FL33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawee","family":"Tanvetyanon","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department, H. Lee Moffitt Cancer Center, FL33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S105396"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.09.050"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.02.013"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.301"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.300"},{"issue":"15","key":"e_1_3_2_10_1","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor Phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan R","year":"2016","unstructured":"Hassan R , ThomasA , PatelMRet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor Phase Ib trial: safety, clinical activity, and PD-L1 expression . J. Clin. Oncol.34 ( S15 ), Abstract 8503 ( 2016 ).","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"e_1_3_2_11_1","article-title":"Second-or third-line nivolumab versus nivo plus ipilimumab in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized Phase II trial","volume":"35","author":"Scherpereel A","year":"2017","unstructured":"Scherpereel A , MazieresJ , GreillierLet al. Second-or third-line nivolumab versus nivo plus ipilimumab in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized Phase II trial . J. Clin. Oncol.35 ( S18 ), Abstract 8507 ( 2017 ).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.635"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_3_2_15_1","first-page":"1","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville R","year":"2017","unstructured":"Bonneville R , KrookMA , KauttoEAet al. Landscape of microsatellite instability across 39 cancer types . Precis. Oncol.1 , 1 \u2013 15 ( 2017 ).","journal-title":"Precis. Oncol."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00544-6"},{"issue":"15","key":"e_1_3_2_17_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.32.4467","article-title":"A Phase II study of pembrolizumab in patients with recurrent thymic carcinoma","volume":"34","author":"Giaccone G","year":"2016","unstructured":"Giaccone G , ThompsonJ , CrawfordJ , McGuireC , ManningM , SubramaniamDS . A Phase II study of pembrolizumab in patients with recurrent thymic carcinoma . J. Clin. Oncol.34 ( S15 ), Abstract 8517 ( 2016 ).","journal-title":"J. Clin. Oncol."}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2017-0177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:55:44Z","timestamp":1715936144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2017-0177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.2217\/imt-2017-0177"],"URL":"https:\/\/doi.org\/10.2217\/imt-2017-0177","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}